Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-09
2011-08-09
Stucker, Jeffrey (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S389100
Reexamination Certificate
active
07994286
ABSTRACT:
Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.
REFERENCES:
patent: 4675187 (1987-06-01), Konishi et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5432018 (1995-07-01), Dower et al.
patent: 5498530 (1996-03-01), Schatz et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5723286 (1998-03-01), Dower et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750373 (1998-05-01), Garrard et al.
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6172197 (2001-01-01), McCafferty et al.
patent: 6204011 (2001-03-01), Kendall et al.
patent: 7273612 (2007-09-01), Klagsbrun et al.
patent: 7335357 (2008-02-01), Klagsbrun et al.
patent: 2002/0132774 (2002-09-01), Klagsbrun et al.
patent: 2006/0166878 (2006-07-01), Klagsbrun et al.
patent: 2008/0076906 (2008-03-01), Klagsbrun et al.
patent: 0 368 684 (1990-05-01), None
patent: 0 404 097 (1996-09-01), None
patent: 0 817 648 (2004-12-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 94/11499 (1994-05-01), None
patent: WO 95/27062 (1995-10-01), None
patent: WO 95/33050 (1995-12-01), None
patent: WO 96/40769 (1996-12-01), None
patent: WO 97/08313 (1997-03-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO 99/29729 (1999-06-01), None
patent: WO 99/29858 (1999-06-01), None
patent: WO 99/29861 (1999-06-01), None
patent: WO 03/102157 (2003-12-01), None
Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate”Arch. Ophthalmology114(1):66-71 (1996).
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders”New England J. of Medicine331(22):1480-1487 (Dec. 1, 1994).
Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution”Science233:747-753 (Aug. 1986).
Bachelder et al., “Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells”Cancer Research61:5736-5740 (Aug. 1, 2001).
Baluk et al., “Cellular Abnormalities of Blood Vessels as Targets in Cancer”Current Opinion in Genetics&Development15:102-111 (2005).
Barbas & Burton, “Selection and evolution of high-affinity human anti-viral antibodies”Trends Biotech14:230-234 (1996).
Barbas et al., “In vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity”Proc. Natl. Acad. Sci. USA91:3809-3813 (1994).
Basile et al., “Class IV Semaphorins Promote Angiogenesis by Stimulating Rho-Initiated Pathways through Plexin-B”Cancer Research64:5212-5224 (Aug. 1, 2004).
Benjamin et al., “A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF”Development125:1591-1598 (1998).
Bergers et al., “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors”J Clin Invest111:1287-1295 (2003).
Berkman et al., “Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms”J. Clin. Invest.91:153-159 (Jan. 1993).
Bielenberg et al., “Neuropilins in neoplasms: Expression, regulation, and function”Exp. Cell Res.312:584-593 (2006).
Bodey et al., “Failure of cancer vaccines: the significant limitations of this approach to immunotherapy”Anticancer Research20(4):2665-2676 (Jul.-Aug. 2000).
Borgstrom et al., “Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy”Cancer Research56(17):4032-4039 (Sep. 1, 1996).
Bradbury and Marks, “Antibodies from phage antibody libraries”J Immunol Methods290:29-49 (2004).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract”Cancer Research53:4727-4735 (Oct. 1, 1993).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer”Human Pathology26(1):86-91 (1995).
Cai et al., “Cloning and Characterization of Neuropilin-1-Interacting Protein: A PSD-95/D1g/Z0-1 Domain-Containing Protein That Interacts with the Cytoplasmic Domain of Neuropilin-1”J. Neurosci.19:6519-6527 (1999).
Carmeliet and Jain, “Angiogenesis in cancer and other diseases”Nature407(6801):249-257 (Sep. 14, 2000).
Carmeliet and Tessier-Lavigne, “Common mechanisms of nerve and blood vessel wiring”Nature436:193-200 (Jul. 14, 2005).
Carter et al., “High LevelEscherichia coliExpression and Production of a Bivalent Humanized Antibody Fragment”Bio/Technology10(2):163-167 (Feb. 1992).
Carter et al., “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy”Proc Natl Acad Sci U S A.89(10):4285-4289 (May 1992).
Champe et al., “Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a”Journal of Biological Chemistry270:1388-1394 (1995).
Chen et al., “Aktl regulates pathological angiogenesis, vascular maturation and permeability in vivo”Nat Med11:1188-1196 (2005).
Chen et al., “Neuropilin-2, a Novel Member of the Neuropilin Family, Is a High Affinity Receptor for the Semaphorins Sema E and Sema IV but Not Sema III”Neuron19:547-559 (Sep. 1997).
Chothia, C. et al., “Conformations of immunoglobulin hypervariable regions”Nature342(21):877-883 (Dec. 28, 1989).
Chothia, et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”J. Mol. Biol.196:901-917 (1987).
Clackson et al., “Making Antibody Fragments Using Phage Display Libraries”Nature352(6336): 624-628 (Aug. 15, 1991).
Connolly, J., “Analytical Molecular Surface Calculation”J. Appl. Cryst.16:548-558 (1983).
Cross et al., “VEGF-receptor signal transduction”Trends Biochem.28(9):488-494 (Sep. 2003).
Cunningham and Wells, “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis”Science244:1081-1085 (Jun. 2, 1989).
de Haard et al., “A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies”Journal of Biological Chemistry274(26):18218-18230 (Jun. 25, 1999).
De Vries et al., “GIPC, a PDZ domain containing protein, interacts specifically with the C terminus of RGS-GAIP”Proc. Natl. Acad. Sci. USA95:12340-12345 (Oct. 1998).
de Wildt et al., “Antibody arrays for high-throughput screening of antibody-antigen interactions”Nat Biotechnol.18(9):989-994 (Sep. 2000).
Deng et al., “Selection of Antibody Single-chain Variable Fragments with Improved Carbohdrate Binding by Phage Display”Journal of Biological Chemistry269:9533-9538 (1994).
Dermer, G., “Another anniversary for the war on cancer”Biotechnology12:320 (1994).
Dickson et al., “Molecular Mechanisms of Axon Guidance”Science298:1959-64 (Dec. 6, 2002).
Dorrell and Friedlander, “Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina”Prog Retin Eye Res25:277-95
Watts Ryan J.
Wu Yan
Genentech Inc.
Gucker Stephen
Kalinowski Grant
Stucker Jeffrey
LandOfFree
Neuropilin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuropilin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuropilin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738742